149 related articles for article (PubMed ID: 37085598)
21. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.
Lalonde E; Ishkanian AS; Sykes J; Fraser M; Ross-Adams H; Erho N; Dunning MJ; Halim S; Lamb AD; Moon NC; Zafarana G; Warren AY; Meng X; Thoms J; Grzadkowski MR; Berlin A; Have CL; Ramnarine VR; Yao CQ; Malloff CA; Lam LL; Xie H; Harding NJ; Mak DYF; Chu KC; Chong LC; Sendorek DH; P'ng C; Collins CC; Squire JA; Jurisica I; Cooper C; Eeles R; Pintilie M; Dal Pra A; Davicioni E; Lam WL; Milosevic M; Neal DE; van der Kwast T; Boutros PC; Bristow RG
Lancet Oncol; 2014 Dec; 15(13):1521-1532. PubMed ID: 25456371
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α.
Gits CM; van Kuijk PF; de Rijck JC; Muskens N; Jonkers MB; van IJcken WF; Mathijssen RH; Verweij J; Sleijfer S; Wiemer EA
BMC Cancer; 2014 Jun; 14():429. PubMed ID: 24927770
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
[TBL] [Abstract][Full Text] [Related]
24. Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas.
Shintani K; Matsumine A; Kusuzaki K; Matsubara T; Satonaka H; Wakabayashi T; Hoki Y; Uchida A
Virchows Arch; 2006 Dec; 449(6):673-81. PubMed ID: 17103226
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
26. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
27. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald V; Litière S; Young R; Messiou C; Lia M; Wardelmann E; van der Graaf W; Gronchi A; Judson I;
Eur J Cancer; 2016 Sep; 64():44-51. PubMed ID: 27323349
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
29. Pyroptosis-Related Gene Signature Is a Novel Prognostic Biomarker for Sarcoma Patients.
Wei D; Lan X; Huang Z; Tang Q; Wang Z; Ma Y; Wei L; Wei Q; Zhao J; Shen J; He S; Song J; Meng L; Tang Q
Dis Markers; 2021; 2021():9919842. PubMed ID: 34904022
[TBL] [Abstract][Full Text] [Related]
30. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
Wiemer EAC; Wozniak A; Burger H; Smid M; Floris G; Nzokirantevye A; Sciot R; Sleijfer S; Schöffski P
Eur J Cancer; 2017 Apr; 75():33-40. PubMed ID: 28214655
[TBL] [Abstract][Full Text] [Related]
31. Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer.
Brooks JM; Menezes AN; Ibrahim M; Archer L; Lal N; Bagnall CJ; von Zeidler SV; Valentine HR; Spruce RJ; Batis N; Bryant JL; Hartley M; Kaul B; Ryan GB; Bao R; Khattri A; Lee SP; Ogbureke KUE; Middleton G; Tennant DA; Beggs AD; Deeks J; West CML; Cazier JB; Willcox BE; Seiwert TY; Mehanna H
Clin Cancer Res; 2019 Sep; 25(17):5315-5328. PubMed ID: 31182433
[TBL] [Abstract][Full Text] [Related]
32. A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients.
Zhang B; Tang B; Gao J; Li J; Kong L; Qin L
J Transl Med; 2020 Sep; 18(1):342. PubMed ID: 32887635
[TBL] [Abstract][Full Text] [Related]
33. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth.
Nakazawa MS; Eisinger-Mathason TS; Sadri N; Ochocki JD; Gade TP; Amin RK; Simon MC
Nat Commun; 2016 Feb; 7():10539. PubMed ID: 26837714
[TBL] [Abstract][Full Text] [Related]
35. Integrated Analysis of TME and Hypoxia Identifies a Classifier to Predict Prognosis and Therapeutic Biomarkers in Soft Tissue Sarcomas.
Xu R; Qi L; Ren X; Zhang W; Li C; Liu Z; Tu C; Li Z
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428766
[TBL] [Abstract][Full Text] [Related]
36. A prognostic nomogram integrating novel biomarkers identified by machine learning for cervical squamous cell carcinoma.
Li Y; Lu S; Lan M; Peng X; Zhang Z; Lang J
J Transl Med; 2020 Jun; 18(1):223. PubMed ID: 32503630
[TBL] [Abstract][Full Text] [Related]
37. A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.
Rade M; Kreuz M; Borkowetz A; Sommer U; Blumert C; Füssel S; Bertram C; Löffler D; Otto DJ; Wöller LA; Schimmelpfennig C; Köhl U; Gottschling AC; Hönscheid P; Baretton GB; Wirth M; Thomas C; Horn F; Reiche K
Mol Med; 2024 Feb; 30(1):19. PubMed ID: 38302875
[TBL] [Abstract][Full Text] [Related]
38. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.
Lalonde E; Alkallas R; Chua MLK; Fraser M; Haider S; Meng A; Zheng J; Yao CQ; Picard V; Orain M; Hovington H; Murgic J; Berlin A; Lacombe L; Bergeron A; Fradet Y; Têtu B; Lindberg J; Egevad L; Grönberg H; Ross-Adams H; Lamb AD; Halim S; Dunning MJ; Neal DE; Pintilie M; van der Kwast T; Bristow RG; Boutros PC
Eur Urol; 2017 Jul; 72(1):22-31. PubMed ID: 27815082
[TBL] [Abstract][Full Text] [Related]
39. The Relationship Between the Tumor Cell Expression of Hypoxic Markers and Survival in Patients With ER-positive Invasive Ductal Breast Cancer.
Shamis SAK; Quinn J; Mallon EEA; Edwards J; McMillan DC
J Histochem Cytochem; 2022 Jul; 70(7):479-494. PubMed ID: 35792080
[TBL] [Abstract][Full Text] [Related]
40. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
